Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
2
×
boston top stories
fda
2
×
life sciences
national blog main
national top stories
new york blog main
roche
san francisco blog main
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
andrew oxtoby
babies
boston
boulder/denver blog main
boulder/denver top stories
breakup
bridge bio pharma
cancer
cancer immunotherapy
center for medicare and medicaid services
ceo
clinical hold
clinical study
combination
commissioner
companion diagnostic
congress
crispr
crispr-cas9
daniel o'day
deals
delisting
democrats
departure
detroit blog main
detroit top stories
What
big
2
×
medicine
2
×
acquire
agreed
billion
bio
bosley's
bosley’s
bridge
broad
bucks
cas
ceo
confidence
crime
crispr
departure
didn’t
editas
exit
foundation
gain
genentech
guiding
katrine
momentum
morning
moves
panels
pay
pays
personnel
picked
profiling
recently
redux
remaining
rest
roche
roundup
Language
Current search:
fda
×
medicine
×
big
×
" boston blog main "
×
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
6 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine